Please login to Zacks.com or register to post a comment.
| No Recent Quote currently available |
|
My Portfolio Tracker One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts. Set yours up today. |
Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.
Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.
Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.
My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.
| Company Name | Symbol | %Change |
|---|---|---|
| VIASAT INC | VSAT | 19.35% |
| OLD SECOND B | OSBC | 5.76% |
| GAMCO INVEST | GBL | 4.61% |
| CORNING INC | GLW | 4.47% |
| SYNCHRONOSS | SNCR | 4.23% |
Please login to Zacks.com or register to post a comment.
Resources
Client Support
Zacks Research is Reported On:
Zacks Investment Research
is an A+ Rated BBB
Accredited Business.
Copyright 2013 Zacks Investment Research
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1986 it has nearly tripled the S&P 500 with an average gain of +26% per year. These returns cover a period from 1986-2011 and were examined and attested by Baker Tilly, an independent accounting firm.
Visit performance for information about the performance numbers displayed above.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This page is temporarily not available. Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext. 9339.
Medical devices and tissue processing company CryoLife ( CRY - Snapshot Report ) recently revealed an equity investment of $3.5 million in ValveXchange Inc., a privately held device company hived out of Cleveland Clinic.
ValveXchange develops life-long heart valve replacement know-how including exchangeable bioprosthetic leaflets. It is an emerging tech company, based in Colorado, developing the first “serviceable” bio-prosthetic heart valve. By raising the probability of time-to-time, less invasive exchange of old leaflet set, younger patients may avoid the utilization of a mechanical valve and its life-long Coumadin anti-coagulation therapy.
Per the deal terms, CryoLife will be given about 19% initial equity in ValveXchange along with certain other rights, such as the ability to negotiate with ValveXchange for distribution rights in Europe. In addition, CryoLife will provide as much as $2 million in extra debt funding using a revolving credit facility.
A spokesperson for CryoLife stated that the novel replaceable bioprosthetic leaflet design of ValveXchange heart valves may have the capability to obviate repeat open heart surgeries (due to long-term wear problems associated with present-day biological valves).
For its part, a senior official of ValveXchange stated that animal studies reveal encouraging data set with valve leaflet and second exchanges proceeding without hitches. The funding will assist first-in-man procedures of its Vitality Exchangeable Heart Valve System, expected later during the year, followed by an anticipated European clinical trial.
The Vitality Exchangeable Heart Valve System brings together the longevity and safety of frequently utilized surgical bioprosthetic valves with the capability to provide less invasive access for transapical valve exchange. Vitality, a two-part valve platform for patients of different ages, may beat the challenges from prolonged leaflet wear and the need for repeated invasive valve replacement operations.
The second generation system from ValveXchange, the Vanguard, is expected to permit implantation and also valve exchange procedures to be performed transapically, via a minor cut between the ribs and a small hole at the apex of the heart, which heal rapidly.
CryoLife is an early mover in the process and distribution of implantable human tissues for usage in cardiac and vascular operations across Canada and the U.S. Among other products, the company’s CryoValve SG pulmonary heart valve, based on its proprietary SynerGraft know-how, received FDA 510(k) clearance for replacement of defective natural or prosthetic pulmonary valves.
CryoLife possesses 10 patents covering heart valve and associated know-how with 10 more patent applications under process. The company competes, in certain niches, with St. Jude Medical ( STJ - Analyst Report ) and Edwards Lifesciences Corp. ( EW - Analyst Report ) .
Read the full Analyst Report on STJ
Read the full Analyst Report on EW
Read the full Snapshot Report on CRY